Although thyroid cells and pancreatic β cells may also undergo inflammatory destruction during ICI treatment (such as autoimmune thyroiditis with an incidence of approximately 10% and type 1 diabetes with a lower incidence of approximately 1%), this usually depends on a specific genetic susceptibility background (such as TPO antibody positivity or HLA susceptibility) and does not have broadly consistent target antigen characteristics like melanocytes (115). Here, TPO is linked to type 1 diabetes mellitus.